Novartis said it will pay $245m to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the US of generic versions of its Exforge hypertension drug.
CVS Health, Kroger, Rite Aid and Walgreens Boots Alliance are among the plaintiffs in the civil litigation, which began in 2018. Novartis and Par were accused of entering an illegal"reverse payment" agreement to delay launches of less expensive, generic versions of Exforge, which treats hypertension to lower blood pressure and reduce the risk of strokes.
Source: Law Daily Report (lawdailyreport.net)
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: